Caribou Biosciences (CRBU) EBIAT (2020 - 2026)
Caribou Biosciences (CRBU) reported EBIAT of -$25.1 million for Q1 2026, up 37.27% year-over-year from -$18.3 million in Q1 2025, and up 5.34% on a QoQ basis from -$26.5 million in Q4 2025.
Caribou Biosciences (CRBU) has 7 years of EBIAT data on file, last reported at -$25.1 million in Q1 2026.
- Quarterly EBIAT rose 37.27% year-over-year to -$25.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$133.2 million (up 9.9% YoY) and the FY2025 annual result came in at -$148.1 million, up 0.67% from the prior year.
- EBIAT rose to -$25.1 million in Q1 2026 per CRBU's latest filing, from -$26.5 million in the prior quarter.
- Across five years, EBIAT topped out at -$10.0 million in Q3 2023 and bottomed at -$54.1 million in Q2 2025.
- The 5-year median for EBIAT is -$28.0 million (2023), against an average of -$30.8 million.
- The widest annual swing landed in 2023, when EBIAT jumped 62.46%; it then plunged 246.77% in 2024.
- Tracing CRBU's EBIAT over 5 years: stood at -$27.0 million in 2022, then declined by 27.85% to -$34.5 million in 2023, then retreated by 2.85% to -$35.5 million in 2024, then climbed by 25.33% to -$26.5 million in 2025, then climbed by 5.34% to -$25.1 million in 2026.
- Per Business Quant, the three latest CRBU EBIAT figures stand at -$25.1 million (Q1 2026), -$26.5 million (Q4 2025), and -$27.5 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 30.90 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Caribou Biosciences | 232.46 Mn | 114.84 Mn | - | -25.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -25.09 Mn |
| Dec 31, 2025 | -26.50 Mn |
| Sep 30, 2025 | -27.55 Mn |
| Jun 30, 2025 | -54.10 Mn |
| Mar 31, 2025 | -39.99 Mn |
| Dec 31, 2024 | -35.49 Mn |
| Sep 30, 2024 | -34.68 Mn |
| Jun 30, 2024 | -37.70 Mn |
| Mar 31, 2024 | -41.23 Mn |
| Dec 31, 2023 | -34.51 Mn |
| Sep 30, 2023 | -10.00 Mn |
| Jun 30, 2023 | -29.52 Mn |
| Mar 31, 2023 | -28.04 Mn |
| Dec 31, 2022 | -26.99 Mn |
| Sep 30, 2022 | -26.65 Mn |
| Jun 30, 2022 | -26.70 Mn |
| Mar 31, 2022 | -19.09 Mn |
| Dec 31, 2021 | -18.48 Mn |
| Sep 30, 2021 | -20.97 Mn |
| Jun 30, 2021 | -14.31 Mn |
| Mar 31, 2021 | -13.16 Mn |
| Dec 31, 2020 | -14.70 Mn |
| Sep 30, 2020 | -7.93 Mn |
| Jun 30, 2020 | -1.87 Mn |
| Mar 31, 2020 | -9.80 Mn |